Evidence map›Paper›PMID 28319075›Full record

ArticleBone marrow transplantation2017

Autologous hematopoietic stem cell transplantation for pediatric multiple sclerosis: a registry-based study of the Autoimmune Diseases Working Party (ADWP) and Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT).

J Burman, K Kirgizov, K Carlson, M Badoglio, G L Mancardi, G De Luca, B Casanova, J Ouyang, R Bembeeva, J Haas and 3 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Review
  4. Article
  5. The EBMT-ADWP and the CIBMTR.Handbook of clinical neurology · 2024
    Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Newer Treatment Approaches in Pediatric-Onset Multiple Sclerosis.Current treatment options in neurology · 2019
    Review
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 13 institutions in 8 countries.

J BurmanDepartment of Neuroscience, Uppsala University Hospital, Uppsala University, Uppsala, Sweden.ORCID http://orcid.org/0000-0002-7045-1806
K KirgizovBMT Department, Russian Children's Research Hospital, Moscow, Russia.
K CarlsonDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.
M BadoglioEBMT Paris Study Office, Hôpital Saint Antoine, Paris, France.
G L MancardiDepartment of Neurosciences, University of Genoa, Genoa, Italy.
G De LucaNeurology Clinic, Multiple Sclerosis Center, Università G. D'Annunzio Chieti-Pescara, Chieti, Italy.
B CasanovaNeuroimmunology Unit, Hospital Universitari i Politècninc La Fe, Valencia, Spain.
J OuyangDepartment of Hematology, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.
R BembeevaNeurosurgery and Genetics of Pediatric Faculty, Department of Neurology, Pirogov Russian National Research Medical University, Moscow, Russia.
J HaasJüdisches Krankenhaus, Berlin, Germany.
P BaderDivision for Stem Cell Transplantation and Immunology, Department for Children and Adolescents, G.W. Goethe University Hospital, Frankfurt am Main, Germany.
J SnowdenDepartment of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust and University of Sheffield, Sheffield, UK.
D FargeParis 7 University, INSERM U1160, Paris, France.
Goethe University Frankfurt · DEHospital Universitari i Politècnic La Fe · ESInserm · FRJüdisches Krankenhaus Berlin · DENanjing Drum Tower Hospital · CNPirogov Russian National Research Medical University · RURussian Children's Clinical Hospital · RUSheffield Teaching Hospitals NHS Foundation Trust · GBSorbonne Université · FRUniversity of Chieti-Pescara · ITUniversity of Genoa · ITUppsala University · SEUppsala University Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autologous hematopoietic stem cell transplantation (aHSCT) is a promising therapy for multiple sclerosis (MS), which has mainly been used in adults. The purpose of this study was to investigate efficacy and adverse events of aHSCT in the treatment of children with MS using data from the European Society for Blood and Marrow Transplantation registry. Twenty-one patients with a median follow-up time of 2.8 years could be identified. PFS at 3 years was 100%, 16 patients improved in expanded disability status scale score and only 2 patients experienced a clinical relapse. The procedure was generally well tolerated and only two instances of severe transplant-related toxicity were recorded. There was no treatment-related mortality, although one patient needed intensive care. aHSCT may be a therapeutic option for children with disease that does not respond to standard care.

Indexed as

AdolescentChildFemaleHematopoietic Stem Cell TransplantationHumansMaleMultiple SclerosisRegistriesTransplantation, AutologousTreatment Outcome

Identifiers

PMID28319075
OpenAlexW2603619943

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.